Overview

Tezacitabine and Oxaliplatin for the Treatment of Patients With Metastatic Colorectal Cancer

Status:
Terminated
Trial end date:
2004-08-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to determine the best dose of tezacitabine when combined with oxaliplatin in patients with metastatic colorectal cancer. This study will also evaluate tumor response to the combination of anti-cancer drugs.
Phase:
Phase 2
Details
Lead Sponsor:
Chiron Corporation
Treatments:
Oxaliplatin
Tezacitabine